Jubilant HollisterStier, a Canada-based pharmaceutical contract manufacturing organization (CMO), in a deal with the Government of Quebec, announced a $77 million capacity expansion at its manufacturing facility in Montreal.

This investment aims to modernize and augment the drug production capacity by over 100% at the site. As part of this initiative, Jubilant HollisterStier will acquire new specialized equipment and equip the plant with a single-use sterile preparation room to maximize the filling process linked to the production of liquid sterile products.

“This modernization project shows the effervescence that is being created in Montreal in the life sciences,” said Pierre Fitzgibbon, Minister of Economy and Innovation and Minister responsible for Regional Economic Development. “To have a more efficient health network, we must increase our health autonomy. The pandemic has shown us how important it is to strengthen our supply chains, and that is exactly what we are doing today.”

Christian Dubé, Minister of Health and Social Services, said, “Quebec has a strong industrial fabric in life sciences, and the modernization of Jubilant HollisterStier’s facilities will further consolidate this key sector. This project will also generate contract development and manufacturing activities for other Quebec biopharmaceutical companies. With the new Québec Life Sciences Strategy, we want to create even more synergies like this between our companies to meet the major health challenges.”

Amit Arora, president, contract manufacturing organization (CMO), Jubilant HollisterStier, said, “This new agreement is a testament to the contributions of our organization during the current pandemic and public health emergencies over the past two decades. Jubilant HollisterStier’s expansion will target large pharmaceutical and biotech companies parenteral products as well as feature a flexible manufacturing platform able to produce several types of vaccines (live, mRNA and inactivated/subunit).